Chelsea Therapeutics‘ (NASDAQ:CHTP) drug candidate for dizziness and fainting in Parkinson’s disease patients has been accepted for priority review by the U.S. Food and Drug Administration. Priority review is reserved for drugs that either offer a major advance in treatment, or provide treatment where no adequate therapy exists. The drug candidate, Northera, already has orphan […]
The new Parkinson’s disease treatment developed by Chelsea Therapeutics (NASDAQ:CHTP) has been submitted to regulators for approval and the company is seeking an expedited review. Charlotte, North Carolina-based Chelsea filed the new drug application for Northera on Wednesday. Chelsea already has orphan drug status on Northera, its lead drug candidate. In its NDA filing, the […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Drug development company Chelsea Therapeutics plans to file a new drug application in the third quarter for its lead drug candidate, an orphan drug for Parkinson’s disease patients. Charlotte, North Carolina-based Chelsea (NASDAQ:CHTP) reaffirmed the plans following correspondence with the U.S. Food and Drug Administration regarding data from a recent study on its drug candidate […]
Chelsea Therapeutics wants to raise $35 million through a stock offering that will finance work on drug candidates for hypotension and rheumatoid arthritis.
Chelsea Therapeutics' low blood pressure drug Northera fails to meet its primary target in phase III clinical trials and the Charlotte, North Carolina-based company now says it is expanding its study of the drug candidate for a different target.